1) They bought in 15,000 shares at about 308 in the first quarter. One would think they would be aggressive buyers at current prices. I believe they are allowed back in the market on Wednesday. Repurchase is still very accretive to earnings, especially with cash sitting on the balance sheet earning very little.
2) Fluid delivery was up 20$ in sales in the quarter, a really big jump. Ophthamology was down versus the rebound first quarter of last year after the 2012 order drop. Over time, Atrion is slowly becoming a fluid delivery company with a nice cardiology side businesses and small eye and other divisions.
3) The tax rate, as they discussed, was up almost 4%.
All in all, the kind of quarter we have come to expect from this company.